EJC Skin Cancer最新文献

{"title":"Melanoma with rhabdomyoblastic features – an aggressive type and therapeutic challenge","authors":"Z. Synowiec","doi":"10.1016/j.ejcskn.2026.100862","DOIUrl":"10.1016/j.ejcskn.2026.100862","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100862"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Assessment of Tebentafusp-Related Cutaneous Toxicity","authors":"M. Rajczykowski , G. Kaminska-Winciorek , M. Straczynski , M. Suchorzepka , K. Galwas , A. Idasiak , B. Ziółkowska , W. Bal , R. Suwinski","doi":"10.1016/j.ejcskn.2026.100865","DOIUrl":"10.1016/j.ejcskn.2026.100865","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100865"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PragmaTIL: A randomized phase II study evaluating an IL-2 analogue (ANV419) versus high-dose IL-2 following tumor-infiltrating lymphocyte (TIL) therapy in advanced melanoma.","authors":"M.J. Lostes Bardaji , V. Galvao , I. Mansfield Noringriis , R. Haunstrup Døssing , S. Klobuch , G. Pretelli , G. Villacampa , A. Lundqvist , S.L. Wickström , M. Donia , V. García-Patos Briones , C. Ferrándiz Pulido , E. Muñoz Couselo , M.A. Franzoi , P. Cacilhas , G. Jacob , F. Le Moal , S. Everhard , I. Creus , X. Villalobos , E. Garralda Cabanas","doi":"10.1016/j.ejcskn.2026.100881","DOIUrl":"10.1016/j.ejcskn.2026.100881","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100881"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to letter Re: Long-term outcomes of cutaneous basal cell and squamous cell carcinomas with < 1 mm close primary surgical excision margins managed in a UK tertiary centre multidisciplinary team","authors":"Benjamin Clay,&nbsp;Robert Manton,&nbsp;John Kiely,&nbsp;Animesh Patel,&nbsp;Amit Roshan","doi":"10.1016/j.ejcskn.2026.101161","DOIUrl":"10.1016/j.ejcskn.2026.101161","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101161"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149004460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study","authors":"Michael Weichenthal,&nbsp;Eva Ellebaek","doi":"10.1016/j.ejcskn.2026.101149","DOIUrl":"10.1016/j.ejcskn.2026.101149","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101149"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148587710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment","authors":"Carl Maximilian Thielmann,&nbsp;Luisa Richter,&nbsp;Henry Karl Tapken,&nbsp;Johanna Andrea Seier,&nbsp;Lisa Schielke,&nbsp;Jan Sternberg,&nbsp;Julia Kretz,&nbsp;Inga Möller,&nbsp;Antje Sucker,&nbsp;Annette Paschen,&nbsp;Lennart Ocker-Serger,&nbsp;Frederik Krefting,&nbsp;Anne Zaremba,&nbsp;Lea Jessica Albrecht,&nbsp;Lisa Zimmer,&nbsp;Elisabeth Livingstone,&nbsp;Georg Lodde,&nbsp;Alpaslan Tasdogan,&nbsp;Jan-Malte Placke,&nbsp;Eva Hadaschik,&nbsp;Klaus Griewank","doi":"10.1016/j.ejcskn.2026.101152","DOIUrl":"10.1016/j.ejcskn.2026.101152","url":null,"abstract":"<div><h3>Background</h3><div><em>KIT</em> alterations occur in distinct melanoma subtypes, yet <em>KIT</em>-mutant melanoma remains clinically and biologically heterogeneous and lacks approved KIT-targeted therapy. We characterized clinico-genomic features of <em>KIT</em>-altered melanoma and described outcomes of patients treated with tyrosine kinase inhibitors (TKI).</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we reviewed 3837 next-generation sequencing (NGS) reports from the Department of Dermatology, University Hospital Essen (2013–2024) and identified 97 patients with <em>KIT</em>-mutated melanoma. Tumors were classified as <em>KIT</em> hotspot (activating, recurrent variants; n = 18) or non-hotspot (n = 79). Clinical characteristics, mutational landscape, number of detected mutations, UV-associated substitution patterns, and survival outcomes were analyzed; five <em>KIT</em>-mutant patients treated with TKIs were described in detail.</div></div><div><h3>Results</h3><div>Most cases were of cutaneous (82/97) origin, while other subgroups included mucosal (7/97) and melanoma of unknown primary (8/97). <em>KIT</em> hotspot mutations were enriched in acral and mucosal primaries and were mutually exclusive with <em>BRAF</em> V600 and <em>NRAS</em> Q61/G12 mutations, whereas non-hotspot tumors frequently harbored canonical drivers (<em>BRAF</em> V600 22.8%, <em>NRAS</em> Q61/G12 17.7%). <em>NF1</em> mutations were markedly enriched in non-hotspot tumors (62.0% vs 16.7%; p &lt; 0.001). In cutaneous melanoma, non-hotspot mutant tumors showed higher number of mutations than hotspot mutant tumors (median 13 vs 3; p &lt; 0.001) and a more pronounced UV mutation signature. Five patients received TKIs (imatinib, ripretinib, sunitinib, nilotinib) with responses ranging from mixed to complete responses.</div></div><div><h3>Conclusions</h3><div><em>KIT</em> hotspot and non-hotspot variants define biologically distinct subsets of <em>KIT</em>-altered melanoma. Non-hotspot <em>KIT</em> variants frequently co-occur with <em>NF1</em>-mutations and high-mutation numbers, supporting a passenger role in many cases, whereas hotspot <em>KIT</em> marks a targetable dependency and warrants repeat profiling at progression.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101152"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking locoregional therapy of Merkel cell carcinoma in the era of immune checkpoint inhibition","authors":"Jürgen C. Becker,&nbsp;Rogerio I. Neves,&nbsp;Piotr Rutkowski","doi":"10.1016/j.ejcskn.2026.101153","DOIUrl":"10.1016/j.ejcskn.2026.101153","url":null,"abstract":"<div><div>Merkel cell carcinoma (MCC) is a highly aggressive yet profoundly immunotherapy-sensitive skin cancer characterized by early nodal and systemic dissemination. Historically, aggressive locoregional treatment was considered essential because therapeutic options for advanced disease were limited. The advent of immune checkpoint inhibitors has fundamentally transformed outcomes in MCC and, for the first time, enabled critical reassessment of established surgical and radiotherapeutic paradigms. Contemporary evidence suggests that intensified locoregional therapy does not consistently improve survival, which appears to be driven primarily by occult systemic disease. Emerging perioperative immunotherapy data therefore support more individualized, biology-driven strategies, including potential de-escalation of local therapy in selected patients while maintaining effective oncologic control.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101153"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatment","authors":"Margot Ricart ,&nbsp;Laurent Mortier ,&nbsp;Stéphane Dalle ,&nbsp;Sophie Dalac ,&nbsp;Caroline Dutriaux ,&nbsp;Henri Montaudié ,&nbsp;Delphine Legoupil ,&nbsp;Eve Maubec ,&nbsp;Marie-Thèrèse Leccia ,&nbsp;Julie De Quatrebarbes ,&nbsp;Florence Brunet-Possenti ,&nbsp;Florence Granel-Brocard ,&nbsp;Jean Philippe Arnault ,&nbsp;Caroline Gaudy-Marqueste ,&nbsp;Wendy Lefevre ,&nbsp;Celeste Lebbe ,&nbsp;Olivier Dereure","doi":"10.1016/j.ejcskn.2026.100782","DOIUrl":"10.1016/j.ejcskn.2026.100782","url":null,"abstract":"<div><h3>Background</h3><div>Specific data regarding Progression-Free Survival (PFS) and treatment maintenance estimated by Time To Next Treatment (TTNT) in patients with advanced melanoma responding to first-line treatments are scarce.</div></div><div><h3>Objective</h3><div>To evaluate and compare in a real-life setting PFS and overall TTNT in patients with advanced melanoma responding to first-line treatment within three therapeutic subsets: BRAF and MEK inhibitors (group 1), anti-PD1 (group 2) and anti-PD1/Anti-CTLA4 immunotherapies (group 3); and to perform comparative analyses of PFS and TTNT according to response depth (complete or partial response), brain metastases (BM), and per-treatment disease progression.</div></div><div><h3>Patients and Methods</h3><div>Patients with unresectable stage III or IV melanoma registered in the French nationwide multicenter Melbase database and responding to first-line immunotherapy or targeted therapy were retrospectively included. Overall and situation-specific PFS and TTNT were assessed and compared within and between therapeutic groups.</div></div><div><h3>Results</h3><div>Median PFS was 10.7 months, 84.6 months, and not reached in group 1, 2 and 3 respectively. No obvious difference was observed between PFS and TTNT for patients receiving targeted therapies (TT) and combined anti-PD1/CTLA4 immunotherapy. Conversely, TTNT largely exceeded PFS in patients receiving anti-PD1 alone, with an increasing gap over time. Similar trends were observed in patients with BM and in those experiencing per-treatment disease progression.</div></div><div><h3>Conclusion</h3><div>First-line combined anti-PD1/Anti-CTLA4 immunotherapy was associated with the most durable response in patients with advanced melanoma considered as responders, compared with anti-PD1 alone or targeted therapy, independently of BM status. Anti-PD1 monotherapy was frequently maintained beyond disease progression, in contrast to targeted therapy.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100782"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing trends in early recurrence of stage I-III melanoma in Norway: A nationwide cohort study, 2008-2021","authors":"A. Giorcelli ,&nbsp;M. Valberg ,&nbsp;A.C. Green ,&nbsp;M.B. Veierød ,&nbsp;D.R. Costa ,&nbsp;J.M. Gran ,&nbsp;H.L. Svendsen ,&nbsp;H. Jespersen ,&nbsp;B.K. Andreassen ,&nbsp;T.E. Robsaham ,&nbsp;R. Ghiasvand","doi":"10.1016/j.ejcskn.2026.100802","DOIUrl":"10.1016/j.ejcskn.2026.100802","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100802"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and survival outcomes of untreated, resectable stage I–III melanoma patients in Serbia","authors":"I. Salatić ,&nbsp;I. Tanasković ,&nbsp;M. Recalde ,&nbsp;B. Dujović ,&nbsp;S. Matković ,&nbsp;M. Đurkić ,&nbsp;J. Filipović ,&nbsp;A. Ivezić ,&nbsp;B. Nikolin ,&nbsp;N. Kolović ,&nbsp;E. Milosavljević ,&nbsp;M. Petronijević ,&nbsp;M. Balić ,&nbsp;A. Popović ,&nbsp;D. Manioti ,&nbsp;L. Kandolf ,&nbsp;B. Rakić ,&nbsp;A. Mijatovic Mrdja","doi":"10.1016/j.ejcskn.2026.100803","DOIUrl":"10.1016/j.ejcskn.2026.100803","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100803"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}